On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

BCHE

butyrylcholinesterase

The BCHE gene provides instructions for producing the pseudocholinesterase enzyme, which plays a critical role in metabolising certain medications, toxins, and may be involved in nerve cell development. The BCHE gene is responsible for encoding the pseudocholinesterase (butyrylcholinesterase) enzyme, primarily produced in the liver and circulating in the bloodstream.

Chromosome 3q26.1 Autosomal recessive HGNC:983 Tier C
BCHE 3q26.1 p arm q arm 3

BCHE is located on the long (q) arm of chromosome 3, at band 3q26.1. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 3 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The BCHE gene, also known as butyrylcholinesterase or pseudocholinesterase E1, contains the genetic blueprint for the pseudocholinesterase enzyme. This enzyme is synthesised in the liver and circulates throughout the blood, where it helps in the breakdown of various compounds. Its primary recognised roles include the metabolism of specific muscle relaxant drugs used during general anaesthesia and the detoxification of certain environmental toxins.

Research also indicates a potential role for pseudocholinesterase in the development and maturation of nerve cells within the brain. Understanding the BCHE gene and its enzyme is important, particularly in pharmacogenomics, as variations can influence an individual's response to certain medical treatments.

What the gene does

The pseudocholinesterase enzyme, encoded by the BCHE gene, serves as a crucial hydrolase in the body. Its main function involves the hydrolysis of ester-containing compounds, effectively breaking them down into simpler molecules. This enzymatic activity is particularly important for the metabolism of certain medications, including succinylcholine and mivacurium, which are muscle relaxants often administered during general anaesthesia. By breaking down these drugs, pseudocholinesterase helps to terminate their action, allowing for the recovery of muscle function, including those involved in breathing.

Beyond drug metabolism, pseudocholinesterase also contributes to the body's defence mechanisms by detoxifying various harmful substances. These include some agricultural pesticides, certain recreational drugs, and naturally occurring compounds like solanine, found in green potato skins. Additionally, evidence suggests the enzyme may have a role in the growth and maturation processes of neurons in the developing brain, although this aspect is still under investigation.

Video: Genetics 101

Chromosome location

The BCHE gene is situated on chromosome 3. Specifically, its location is mapped to the long arm (q arm) of chromosome 3, at position 26.1 (3q26.1). This genomic address indicates its precise place within the human genome.

Protein structure

The pseudocholinesterase protein encoded by the BCHE gene consists of 602 amino acids. Domain architecture has not been experimentally characterised in detail for this protein.

Key variants

Genetic variations, or variants, within the BCHE gene can alter the function or production of the pseudocholinesterase enzyme. These variants can range from single nucleotide changes to larger alterations. Depending on the specific change, a variant might lead to a dysfunctional enzyme, an enzyme with reduced activity, or even prevent the production of the enzyme altogether. These alterations are the underlying cause of conditions such as pseudocholinesterase deficiency.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for BCHE.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.1004T>C
single nucleotide variant
p.Leu335Pro Pathogenic/Likely pathogenic ★★☆☆ Deficiency of butyrylcholinesterase
c.100del
Deletion
p.Ile34fs Pathogenic ★★☆☆ BCHE-related disorder
c.1027dup
Duplication
p.Thr343fs Pathogenic/Likely pathogenic ★★☆☆ Deficiency of butyrylcholinesterase
c.1072T>A
single nucleotide variant
p.Leu358Ile Pathogenic/Likely pathogenic ★★☆☆ Deficiency of butyrylcholinesterase
c.1129G>T
single nucleotide variant
p.Glu377Ter Pathogenic/Likely pathogenic ★★☆☆ Deficiency of butyrylcholinesterase
c.1177G>C
single nucleotide variant
p.Gly393Arg Pathogenic/Likely pathogenic ★★☆☆ Deficiency of butyrylcholinesterase
c.1240C>T
single nucleotide variant
p.Arg414Cys Pathogenic/Likely pathogenic ★★☆☆ Deficiency of butyrylcholinesterase
c.1354C>T
single nucleotide variant
p.Arg452Ter Pathogenic/Likely pathogenic ★★☆☆ Deficiency of butyrylcholinesterase
c.1584T>A
single nucleotide variant
p.Tyr528Ter Pathogenic/Likely pathogenic ★★☆☆ Deficiency of butyrylcholinesterase
c.428G>A
single nucleotide variant
p.Gly143Asp Pathogenic ★★☆☆ BCHE-related disorder

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Variants in the BCHE gene are primarily associated with pseudocholinesterase deficiency. This condition results in an increased sensitivity to specific substances, most notably the muscle relaxants succinylcholine and mivacurium. Individuals with this deficiency may experience prolonged effects from these medications, which can lead to extended periods of muscle paralysis and respiratory depression following general anaesthesia.

No condition pages are linked to this gene yet. This does not mean it has no associated conditions.

Inheritance pattern

Conditions caused by pathogenic BCHE variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous BCHE carrier status across ancestry groups?

UK clinical status

Frequently asked questions

What is the main role of the BCHE gene?

The BCHE gene provides instructions for the pseudocholinesterase enzyme, which breaks down specific medications like succinylcholine and mivacurium, and also helps detoxify various harmful substances.

What is pseudocholinesterase deficiency?

Pseudocholinesterase deficiency is a condition caused by BCHE gene variants, leading to an inability to properly break down certain drugs and toxins, often resulting in prolonged effects of muscle relaxants used in anaesthesia.

How can BCHE gene variants affect medication response?

BCHE gene variants can cause the pseudocholinesterase enzyme to function improperly or not be produced at all. This can lead to an increased sensitivity and prolonged effects from muscle relaxants such as succinylcholine and mivacurium during surgical procedures.

References

  1. Garcia DF, Oliveira TG, Molfetta GA. Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine. Genetics and molecular biology. 2011. PMID: 21637541
  2. Howard TD, Hsu FC, Grzywacz JG. Evaluation of candidate genes for cholinesterase activity in farmworkers exposed to organophosphorus pesticides: association of single nucleotide polymorphisms in BCHE. Environmental health perspectives. 2010. PMID: 20529763
  3. Zelinski T, Coghlan G, Mauthe J. Molecular basis of succinylcholine sensitivity in a prairie Hutterite kindred and genetic characterization of the region containing the BCHE gene. Molecular genetics and metabolism. 2007. PMID: 17166756
  4. Gätke MR, Bundgaard JR, Viby-Mogensen J. Two novel mutations in the BCHE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia. Pharmacogenetics and genomics. 2007. PMID: 18075469
  5. Levano S, Ginz H, Siegemund M. Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine. Anesthesiology. 2005. PMID: 15731589
  6. Yen T, Nightingale BN, Burns JC. Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. Clinical chemistry. 2003. PMID: 12881446
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 11 October 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .